%PDF-1.4
%
62 0 obj
<>
endobj
59 0 obj
<>
endobj
122 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-11-26T16:43:51Z
2024-03-28T12:33:20-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T12:33:20-07:00
application/pdf
Heather
201125 july
uuid:a2c19a4b-1dd1-11b2-0a00-b90827bd3700
uuid:a2c19a4d-1dd1-11b2-0a00-5b0000000000
endstream
endobj
48 0 obj
<>
endobj
49 0 obj
<>
endobj
63 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
17 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
25 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
33 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
144 0 obj
[148 0 R]
endobj
145 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.1981 Tw 10 0 0 10 54 713.1616 Tm
[(IgG glycoprotein may be dif)17.8 (ferent in healthy individuals)]TJ
0.0193 Tw 0 -1.2 TD
(and patients with RA, even if they contain similar oligosac-)Tj
0.0567 Tw T*
(charide compositions, is suggested when the relative inten-)Tj
-0.03349 Tw T*
(sities of the asialylated digalactosyl \(band 1\) and agalactosyl)Tj
0.0843 Tw T*
(\(band 4\) are correlated with the extent of lectin binding to)Tj
0.1396 Tw T*
[(gal and GlcNAc. In individuals with RA)-334.7 (we investigated,)]TJ
0.036 Tw T*
(very good correlation was found indicating that an increase)Tj
0.17529 Tw T*
(in the appearance of agalactosyl structures can be recog-)Tj
0.1933 Tw T*
[(nized by both techniques. However)39.8 (, no such correlations)]TJ
0.0094 Tw T*
[(were apparent in healthy individuals. )17.8 (There are a number of)]TJ
-0.00011 Tc 0.10381 Tw T*
(possible reasons for this. It may be that other sugar varia-)Tj
0 Tc 0.0526 Tw T*
[(tions are occurring such that, perhaps, there are dif)17.8 (ferences)]TJ
0.03191 Tw T*
(in the extent of core fucosylation, bisecting GlcNAc or Fab)Tj
0.19099 Tw T*
[(glycosylation. )17.8 (This seems unlikely)65 (, as the electrophoretic)]TJ
0.02271 Tw T*
(mobility of the 6 bands was similar in all individuals inves-)Tj
0.1436 Tw T*
(tigated, and conservation of sugar structure has also been)Tj
0.2328 Tw T*
[(confirmed with HPLC technology)64.9 (. )54.8 (Alternatively)65 (, perhaps)]TJ
0.02319 Tw T*
(there are subtle amino acid changes that result in the sugars)Tj
0.0912 Tw T*
[(adopting a dif)17.8 (ferent spacial configuration, which results in)]TJ
0.1107 Tw T*
[(more ef)17.8 (fective binding of the 2 lectins in individuals with)]TJ
-0.00011 Tc -0.0218 Tw T*
[(RA. )17.8 (This is unlikely)64.8 (, as such RA)-173.3 (associated dif)17.7 (ferences have)]TJ
0 Tc 0.02499 Tw T*
(not previously been detected.)Tj
-0.00011 Tc -0.0204 Tw 1.2 -1.2 Td
[(W)79.7 (e report the successful use of fluorophore linked carbo-)]TJ
0.21181 Tw -1.2 -1.2 Td
(hydrate electrophoresis in the analysis of IgG associated)Tj
0 Tc 0.2233 Tw T*
(oligosaccharides in healthy individuals and patients with)Tj
0.0051 Tc 0.3698 Tw T*
(rheumatic diseases. Unique oligosaccharide profiles or)Tj
0 Tc 0.1859 Tw T*
(sugar prints have been shown to be associated with RA,)Tj
0.21359 Tw T*
[(PsA, and )54.9 (AS, and these were not solely associated with)]TJ
0 Tw T*
(agalactosylation.)Tj
-0.0215 Tw 1.2 -1.2 Td
[(In addition, it would appear that the RA)-173.6 (IgG glycoprotein)]TJ
0.1219 Tw -1.2 -1.2 Td
[(has a dif)17.8 (ferent appearance from that derived from healthy)]TJ
-0.0282 Tw T*
[(individuals. )17.8 (These data raise the possibility that FCE may be)]TJ
0.019 Tc 0.3559 Tw T*
[(utilized in the early diagnosis and dif)17.8 (ferentiation of)]TJ
0 Tc 0.1644 Tw T*
(rheumatic diseases and may also be an additional tool to)Tj
0.30679 Tw T*
(investigate the pathogenic mechanisms leading to these)Tj
-0.00011 Tc 0 Tw T*
(disorders.)Tj
/TT1 1 Tf
0 -2.4 TD
(ACKNOWLEDGMENT)Tj
/TT0 1 Tf
0.1521 Tw 8 0 0 8 54 259.1616 Tm
[(W)79.7 (e thank Dr)54.8 (. O. FitzGerald and Dr)54.8 (. D. Mulherin of University College)]TJ
-0.0106 Tw 0 -1.25 TD
[(Dublin for sera from patients with psoriatic arthritis, and Dr)54.8 (. )54.9 (A. Ebringer of)]TJ
0 Tc 0.2787 Tw T*
[(the Division of Biomolecular Sciences, King\222)54.9 (s College, University of)]TJ
0.02499 Tw T*
(London, for sera from patients with ankylosing spondylitis.)Tj
/TT1 1 Tf
-0.00011 Tc 0 Tw 10 0 0 10 54 205.1616 Tm
(REFERENCES)Tj
/TT0 1 Tf
0 Tc 0.0249 Tw 8 0 0 8 61 195.1616 Tm
[(1.)-875 (Axford JS, Sumar N, )54.8 (Alavi )54.8 (A, et al. Changes in normal)]TJ
1.675 -1.25 Td
(glycosylation mechanisms in autoimmune rheumatic disease. J Clin)Tj
T*
(Invest 1991;34:357-61.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(2.)-875.1 (Parekh RB, Roitt IM, Isenber)17.7 (g DA, Dwek RA, )54.8 (Ansell BM,)]TJ
1.675 -1.25 Td
[(Rademacher )17.7 (TW)91.7 (. Galactosylation of IgG-associated)]TJ
0 Tc T*
(oligosaccharides: reduction in patients with adult and juvenile onset)Tj
T*
[(rheumatoid arthritis and relation to disease activity)64.9 (. Lancet)]TJ
0 Tw T*
(1988;1:966-9.)Tj
0.0249 Tw 31.325 73.671 Td
[(3.)-875 (Sumar N, Bodman K, Rademacher )17.7 (TW)91.8 (, et al. )54.8 (Analysis of)]TJ
1.675 -1.25 Td
(glycosylation changes in IgG using lectins. J Immunol Methods)Tj
0 Tw T*
(1990;131:127-36.)Tj
0.02499 Tw -1.675 -1.25 Td
[(4.)-875 (T)69.8 (suchiya N, Endo )17.8 (T)74 (, Matsuta K, et al. Detection of glycosylation)]TJ
1.675 -1.25 Td
(abnormality in rheumatoid IgG using N-acetylglucosamine-specific)Tj
T*
[(Psathyrella velutina lectin. J Immunol 1993;151:1)36.9 (137-46.)]TJ
-1.675 -1.25 Td
[(5.)-875 (Y)100.1 (ouinou P)110.8 (, Pennec )36.8 (YL, Casburn-Budd R, Dueymes M, Letoux G,)]TJ
1.675 -1.25 Td
[(Lamour )54.8 (A. Galactose terminating oligosaccharides of IgG in)]TJ
-0.00011 Tc T*
[(patients with primary Sj\366gren\222)54.8 (s syndrome. J )54.8 (Autoimmun)]TJ
0 Tc 0 Tw T*
(1992;5:393-400.)Tj
0.02499 Tw -1.675 -1.25 Td
[(6.)-875 (Rook GA, Steele J, Rademacher )17.8 (T)74 (. )54.9 (A)-219.8 (monoclonal antibody raised)]TJ
1.675 -1.25 Td
[(by immunising mice with Group )54.9 (A)-219.8 (streptococci binds to agalactosyl)]TJ
-0.00011 Tc T*
[(IgG from rheumatoid arthritis. )54.8 (Ann Rheum Dis 1988;47:247-50.)]TJ
0 Tc -1.675 -1.25 Td
[(7.)-875 (Jackson P)110.8 (. )17.7 (The use of polyacrylamide-gel electrophoresis for the)]TJ
1.675 -1.25 Td
(high resolution separation of reducing saccharides labelled with the)Tj
T*
(fluorophore 8-aminonaphthalene-1,3,6-trisulphonic acid. Detection)Tj
T*
(of picomolar quantities by an imaging system based on a cooled)Tj
T*
[(char)17.8 (ge-coupled device. Biochem J 1990;270:705-13.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(8.)-875.1 (Jackson P)110.7 (. Fluorophore assisted carbohydrate electrophoresis: a new)]TJ
0 Tc 1.675 -1.25 Td
[(technology for the analysis of glycans. Biochem Soc )17.8 (T)34.9 (rans)]TJ
0 Tw T*
(1993;21:121-5.)Tj
0.0249 Tw -1.675 -1.25 Td
[(9.)-875 (Parekh R, Isenber)17.8 (g D, Rook G, Roitt I, Dwek R, Rademacher )17.7 (T)74 (. )54.8 (A)]TJ
1.675 -1.25 Td
(comparative analysis of disease-associated changes in the)Tj
-0.00011 Tc T*
[(galactosylation of serum IgG. J )54.8 (Autoimmun 1989;2:101-14.)]TJ
0 Tc -2.175 -1.25 Td
[(10.)-875 (Y)100.1 (oung )54.9 (A, Sumar N, Bodman K, et al. )54.9 (Agalactosyl-IgG: )54.9 (An aid to)]TJ
2.175 -1.25 Td
[(dif)17.8 (ferential diagnosis in early synovitis. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(1991;34:1425-9.)Tj
0.0249 Tw -2.1381 -1.25 Td
[(1)36.9 (1.)-875 (Sumar N, Isenber)17.8 (g DA, Bodman KB, et al. Reduction in IgG)]TJ
2.1381 -1.25 Td
(galactose in juvenile and adult onset rheumatoid arthritis measured)Tj
T*
[(by a lectin binding method and its relation to rheumatoid factor)54.9 (.)]TJ
T*
(Ann Rheum Dis 1991;50:607-10.)Tj
-2.175 -1.25 Td
[(12.)-875 (T)69.8 (omana M, Schrohenloher RE, Koopman )17.7 (WJ, )54.8 (Alarcon GS, Paul)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(W)110.7 (A. )54.8 (Abnormal glycosylation of serum IgG from patients with)]TJ
0 Tc T*
[(chronic inflammatory diseases. )54.9 (Arthritis Rheum 1988;31:333-8.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(13.)-875.1 (W)79.7 (atson M, Rudd PM, Bland M, Dwek RA, )54.8 (Axford JS. Sugar)]TJ
0 Tc 2.175 -1.25 Td
[(printing rheumatic diseases: )54.9 (A)-219.8 (potential method for diagnosis and)]TJ
T*
[(dif)17.8 (ferentiation using immunoglobulin G oligosaccharides. )54.9 (Arthritis)]TJ
T*
(Rheum 1999;42:1682-90.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(14.)-875.1 (Malhotra R, )17.7 (W)79.7 (ormald MR, Rudd PM, Fischer PB, Dwek RA, Sim)]TJ
0 Tc 2.175 -1.25 Td
(RB. Glycosylation changes of IgG associated with rheumatoid)Tj
T*
(arthritis can activate complement via the mannose binding protein.)Tj
T*
(Nature Medicine 1995;1:237-43.)Tj
-2.175 -1.25 Td
[(15.)-875 (Soltys )54.8 (AJ, Hay FC, Bond )54.8 (A, et al. )17.7 (The binding of synovial tissue-)]TJ
2.175 -1.25 Td
(derived human monoclonal immunoglobulin M rheumatoid factor)Tj
T*
[(to immunoglobulin G preparations of dif)17.8 (fering galactose content.)]TJ
T*
(Scand J Immunol 1994;40:135-43.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(16.)-875.1 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
2.175 -1.25 Td
[(Rheumatism )54.8 (Association 1987 revised criteria for the classification)]TJ
0 Tc T*
[(of rheumatoid arthritis. )54.8 (Arthritis Rheum 1988;31:315-24.)]TJ
-2.175 -1.25 Td
[(17.)-875 (Bennet P)110.8 (, Burch )17.7 (T)74 (. Population studies of rheumatic diseases.)]TJ
2.175 -1.25 Td
(Amsterdam: Excerpta Medica Foundation; 1968:456-7.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(18.)-875.1 (Bond )54.8 (A, Jones MG, Hay FC. Human IgG preparations isolated by)]TJ
0 Tc 2.175 -1.25 Td
[(ion-exchange or protein G af)17.8 (finity chromatography dif)17.8 (fer in their)]TJ
T*
(glycosylation profiles. J Immunol Methods 1993;166:27-33.)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT2 1 Tf
8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2001; 28:7)Tj
0 Tw -46.2952 -0.0313 Td
(1536)Tj
ET
0 0 0 0 scn
/GS0 gs
103.98 59.08 407.5 -10.83 re
f*
0.5 w
103.98 59.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
109 0 obj
<>
endobj
127 0 obj
<>
endobj
70 0 obj
<>
endobj
83 0 obj
<>
endobj
67 0 obj
<>
endobj
66 0 obj
<>
endobj
104 0 obj
<>stream
HV lTf{6c}!70`se^Le`9"$R(4P!@ GJ
Gp"B~om $R] mP_[?[`N騒JU ]z~vׂh~U*'8@1|Sc :G+;761^}TPqL+ZQ9o~Ng102Q_+џW-}5`:EߪYsYwmjNY߿dB:yDx J
ҝ`2ZRjPqQnHPViFׄ! iwqLq{DN.^l@奨
rhV/^1ctE:zC^BTb)X@F;s&L$w{|ia^N
a@1iG,"NO